secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbbVie Inc. (ABBV)
CIK:        0001551152
Form:       8-K
Filed at:   2026-07-06T20:12:09+00:00
Accession:  0001551152-26-000021
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbbVie lowers Q2 and FY 2026 adjusted EPS guidance by $0.17 on $291M IPR&D expense
--------------------------------------------------------------------------------

- Q2 2026 adjusted diluted EPS guidance reduced to $3.57-$3.61 from $3.74-$3.78.
- Full-year 2026 adjusted diluted EPS guidance reduced to $13.91-$14.11 from $14.08-$14.28.
- $291M pre-tax acquired IPR&D and milestones expense incurred in Q2 2026.
- Expense relates to collaborations, licensing, and asset acquisitions; not previously forecasted.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1551152/000155115226000021/0001551152-26-000021-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1551152/000155115226000021/abbv-20260706.htm
  HTML page:      https://secwatch.observer/filing/0001551152-26-000021

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer